dotMD.com
Find a Doctor
✓ Translated by DotMD AI Clinical Council Source: American heart journal • Phase III Randomized Trial
Verify Primary Source: NIH PubMed PMID #42419438 ↗

Phase III Randomized Trial: Comparative effectiveness of torsemide vs furosemide in the management of heart failure patients: Win-ratio reanalysis of the TRANSFORM-HF trial (N = 2,859)

Original Paper Title: “Comparative effectiveness of torsemide vs furosemide in the management of heart failure patients: Win-ratio reanalysis of the TRANSFORM-HF trial”

Elena Rostova (AI Quant) Rigor Score
90 / 100
Sample Size (Participants)
N = 2,859
Evidence Classification
Phase III Randomized Trial
Sarah Jenkins, RN (AI Plain-English Editor) • Key Takeaways
  • The overall WR comparison between torsemide and furosemide showed no statistically significant difference in the primary 12-month analysis. The WR framework provided an interpretive decomposition across outcome domains but did not establish superiority of either loop diuretic strategy. All findings should be considered exploratory.
  • Study Design & Sample: Phase III Randomized Trial published in American heart journal (N = 2859 human participants).
  • Biostatistical Rigor Score: 90/100 audited by Elena Rostova (AI Biostatistician & openFDA Quant).

What the Study Found (In Plain English)

Published in American heart journal (2026), this phase iii randomized trial evaluating 2,859 human participants investigated: Loop diuretics are widely used for managing congestion in patients with heart failure (HF). Key clinical takeaway: The overall WR comparison between torsemide and furosemide showed no statistically significant difference in the primary 12-month analysis. The WR framework provided an interpretive decomposition across outcome domains but did not establish superiority of either loop diuretic strategy. All findings should be considered exploratory.

Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers

Primary Endpoint & Quantitative Summary (American heart journal, 2026-11-15; N = 2859; Rigor 90/100): The overall WR comparison between torsemide and furosemide showed no statistically significant difference in the primary 12-month analysis. The WR framework provided an interpretive decomposition across outcome domains but did not establish superiority of either loop diuretic strategy. All findings should be considered exploratory.

Study Limitations & Caveats Before You Act

Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Phase III Randomized Trial). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.

Related DotMD Clinical Hubs & Price Ledgers

Rx: torsemide → Rx: furosemide → Rx: furosemide-injection-80-mg-10-ml → Rx: potassium-chloride → Condition: thalassemia → Condition: heart-murmur →
Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data

Ask our AI Specialists anything about PMID 42419438: Phase III Randomized Trial: Comparative effectiveness of torsemide vs furosemide in the management of heart failure patients: Win-ratio reanalysis of the TRANSFORM-HF trial (N = 2,859)

3 of 3 Free Questions Remaining